- Vertex Pharmaceuticals Inc has priced its three-drug combination for cystic fibrosis at $311,503 per year, after winning early U.S. approval on Monday.
The U.S. Food and Drug Administration approval, which comes five months ahead of the agency’s previously announced action date, greatly expands the percentage of cystic fibrosis patients that Vertex can treat. Trikafta is the first approved treatment that is effective for patients 12 years and older, who have a genetic mutation which affects 90% of CF patients or roughly 27,000 people in the United States, the agency said.
However, the approval comes at a time when the drugmaker has been receiving push back from healthcare payers for the price of its existing CF therapies.
I can’t even believe we “sell” medicines at these prices. BigPharma
Shameful
This is capitalism at its worst; 6-figure Rx cost due to short life spans of CF patients.
It's a good thing only extremely wealthy people get cystic fibrosis.
They need to rot in hell
Medicalpervision disgusting
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Allure_magazine - 🏆 473. / 51 Read more »